INTRODUCTION {#cesec10}
============

Infectious bronchitis virus (**IBV**) causes an acute and highly contagious viral disease of chickens that is characterized by respiratory signs, nephritis, and reduced egg reproduction ([@bib7]). Among the IBV structural proteins, the spike glycoprotein S1 subunit is responsible for attachment to the host cellular membrane, induction of neutralization, and hemagglutination of inhibiting antibodies ([@bib4]; [@bib5]). Because of the high rates of *S1* gene mutation, several IBV serotypes or antigenic variant strains have been reported in many countries ([@bib5]). In general, different serotypes of the virus do not confer cross protection against each other ([@bib14]), and cross protection tends to diminish as the degree of amino acid identity between the S1 proteins of 2 IBV strains decreases ([@bib11]). However, some strains of the virus are effective at inducing cross protection against other serotypes or genotypes; these are referred to as protectotypes. Protectotypes have been suggested as a valuable method for the development of strategies to control IBV infections ([@bib9]).

A variant IBV strain identified as QXIBV that was first reported in China ([@bib31]) appears to have become widespread in Eurasia ([@bib12]; [@bib26]). In addition, QX-like nephropathogenic strains have increased the genetic diversity of IBV in the field and caused economic losses in the poultry industry ([@bib30]). Our previous study revealed that QXIBV strain originating from China has been introduced in Korea and has formed a variant virus by recombination with the Korean nephropathogenic strain (KM91 strain; [@bib22]). Furthermore, more recently, some IBV strains formed a new cluster that is very distant from all major genogroups in the phylogenetic tree of the IBV *S1* gene. Because the emergence of new variant strains complicates disease control, there is a concern about whether commercial IBV vaccines could provide protection against these new IBV strains. Nevertheless, genetic and protectotypic characterization of new variant IBV strains remains largely undone.

The present study involved a phylogenetic analysis of the *S1* gene to compare new IBV isolates with commercial vaccine strains and other Korean IBV field isolates. Moreover, we investigated the cross protective efficacy of 2 commercial IBV vaccine strains against new variant IBV strains. The results of the present study might provide information for future IBV vaccination strategies.

MATERIALS AND METHODS {#cesec20}
=====================

Viruses {#cesec30}
-------

Twenty-three new variant IBV isolates obtained from natural outbreak cases of IBV and 2 different commercially available vaccines (K2 strain of the nephropathogenic type and H120 strain of the Mass serotype) were used ([Table 1](#tbl1){ref-type="table"} ). All isolates were propagated in 10-d-old specific-pathogen-free (**SPF**) embryonated chicken eggs (Hy-Vac, Adel, IA) at 37°C for 48 h. The allantoic fluid from eggs infected with each isolate was harvested and frozen at −70°C until use.Table 1Field isolates of infectious bronchitis virus (IBV) used in this studyIBV isolate (new cluster)Type of birdYear of isolationLesion[1](#tbl1fn1){ref-type="table-fn"}Tissue[2](#tbl1fn2){ref-type="table-fn"}Accession no.K716 (1)Broiler2005RSTra, Kid, CTHM486962K1585 (1)Broiler breeder2007RS, EDCTHM486953K183 (1)Korean native chicken2007RS, EDCTHM486954K426 (1)Broiler2008NSTraHM486955K33 (1)Broiler2009RS, NKidHM486956K40 (1)Broiler2009RS, NTra, Kid, CTHM486957K74 (1)Broiler2009RS, NKidHM486958K119 (2)Broiler breeder2009RSTraJF804680K273 (2)Broiler breeder2009RSTra, CTJF804687K308 (2)Layer2009RSTra, CTJF804689K344 (1)Broiler2009RSTra, CTHM486959K23 (2)Broiler2010RSTraJF804677K26 (2)Broiler breeder2010RS, EDTra, Kid, CTJF804678K46 (2)Broiler breeder2010RSTraJF804679K88 (1)Broiler2010RS, NTra, Kid, CTHM486960K147 (1)Broiler2010RS, NTra, Kid, CTHM486961K194 (1)Korean native chicken2010RS, NTra, Kid, CTJF804681K201 (1)Broiler2010RS, NTra, Kid, CTJF804682K226 (1)Broiler2010RS, NTra, Kid, CTJF804683K235 (1)Broiler2010RS, NTra, Kid, CTJF804684K236 (1)Broiler2010RS, NTra, Kid, CTJF804685K245 (1)Korean native chicken2010RS, NTra, Kid, CTJF804686K307 (1)Broiler2010RS, NTra, Kid, CTJF804688[^1][^2]

Chickens {#cesec40}
--------

The SPF White Leghorn chickens (Nam-Deog Sanitek Co., Icheon, Korea) were maintained in positive pressure high-efficiency particulate air-filtered stainless steel isolation cabinets (Three Shine, Daejeon, Korea) under constant illumination within a biosafety level-2 laboratory. All study procedures and animal care activities were conducted in accordance with the national and institutional guidelines for the care and use of laboratory animals (Seoul, Korea).

Viral RNA Extraction, Reverse-Transcription PCR, and DNA Sequencing {#cesec50}
-------------------------------------------------------------------

Viral RNA was extracted from virus-infected allantoic fluid using an RNeasy minikit (Qiagen, Gaithersburg, MD) following the manufacturer\'s instructions. The primer sets (forward: 5′- TAG TGA CCC TTT TGT GTG CAC TAT -3′; and reverse: 5′- GTT TGT ATG TAC TCA TCT GTA AC -3′) were designed for the amplification of the IBV *S1* gene. Reverse transcription (**RT**) was done using Moloney murine leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA) and a reverse primer. For the PCR reaction, EX-Taq polymerase (Takara, Otsu, Shiga, Japan) and the forward primer were added to the RT reaction. The PCR was performed by 40 cycles of denaturation (94°C for 10 s), annealing (53°C for 90 s), and polymerization (72°C for 90 s). The predenaturation step was at 94°C for 20 s and the postpolymerization step was at 72°C for 5 min. The amplified sequences were analyzed by 1.5% agarose gel electrophoresis.

The amplified DNA products were purified using a gel extraction kit (Elpis Biotech, Daejeon, Korea) and the purified products were ligated into a pGEM-T vector (Promega, Fitchburg, WI). All 23 clones were sequenced with a BigDye Terminator v3.1 Cycle Sequencing Kit and products were analyzed on the ABI PRISM 3730xl genetic analyzer (Applied Biosystems, Foster City, CA). The nucleotide sequences for the *S1* genes have been submitted to GenBank (<http://www.ncbi.nlm.nih.gov/genbank/>) under the accession numbers listed in [Table 1](#tbl1){ref-type="table"}.

Comparison of S1 Genes and Phylogenetic Analyses {#cesec60}
------------------------------------------------

The nucleotide sequences of the *S1* gene of the IBV isolates were compiled, and the amino acid sequences were deduced using Bioedit v7.0.9.0 ([@bib13]). The 69 IBV reference strains were retrieved from the GenBank database. Sequence analysis of partial *S1* gene nucleotide positions 25 to 1611 (numbering is in reference to the Mass41 strain) were performed with the ClustalW multiple alignment method. The phylogenetic tree was constructed with the neighbor-joining method with 1,000 bootstrap replicates using MEGA version 4 ([@bib28]).

Cross-Protection Study {#cesec70}
----------------------

In total, 120 three-wk-old SPF chickens were divided into 12 groups of 10 chicks. Eight groups were immunized intraocularly with H120 or K2 strain at 10^3.0^ 50% egg infective dose (**EID~50~**), whereas the other 4 groups were kept as nonimmunized controls. Three weeks after immunization, all of the birds were challenged intraocularly with 10^4.5^ EID~50~ of 3 recombinant strains belonging to the new genetic cluster 1 (K716/05, K40/09, and K245/09) and one variant strain belonging to the new genetic cluster 2 (K26/09; [Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"} ). Five days after the challenge, the challenge virus was reisolated from the trachea and kidney of the birds by inoculating 9- to 11-d-old embryonated SPF chicken eggs to evaluate the cross-protective efficacy of the commercial vaccines.Table 2Protective effects in 3-wk-old specific-pathogen-free chickens immunized with H120 and K2 against a challenge with new variant infectious bronchitis virus (IBV) isolates[1](#tbl2fn1){ref-type="table-fn"}No. of challenge virus isolated/ no. of challengedTracheaKidneyIBV strain immunizedGenogroup of challenge virusIBV strain of challenge virusControlVaccinatedControlVaccinatedH120New cluster 1K245/0910/1010/1010/108/10K40/0910/1010/1010/109/10K716/0510/109/1010/105/10New cluster 2K26/109/107/103/101/10K2New cluster 1K245/0910/101/10[\*\*\*](#tbl2fn4){ref-type="table-fn"},[†††](#tbl2fn7){ref-type="table-fn"}10/100/10[\*\*\*](#tbl2fn4){ref-type="table-fn"},[†††](#tbl2fn7){ref-type="table-fn"}K40/0910/105/10[\*](#tbl2fn2){ref-type="table-fn"},[†](#tbl2fn5){ref-type="table-fn"}10/101/10[\*\*\*](#tbl2fn4){ref-type="table-fn"},[††](#tbl2fn6){ref-type="table-fn"}K716/0510/103/10[\*\*](#tbl2fn3){ref-type="table-fn"},[†](#tbl2fn5){ref-type="table-fn"}10/100/10[\*\*\*](#tbl2fn4){ref-type="table-fn"},[†](#tbl2fn5){ref-type="table-fn"}New cluster 2K26/109/100/10[\*\*\*](#tbl2fn4){ref-type="table-fn"},[††](#tbl2fn6){ref-type="table-fn"}3/100/10[^3][^4][^5][^6][^7][^8][^9]Figure 1Infectious bronchitis virus (IBV) phylogenetic tree of *S1* genes. The tree is based on the sequence of the *S1* genes from the 23 IBV isolates and the 69 reference strains. ClustalW alignment method for *S1* nucleotide positions 25 to 1611 corresponding to those of strain Mass41 (GenBank accession number X04722; <http://www.ncbi.nlm.nih.gov/genbank/>). The IBV isolates used in this study are marked in bold and 2 vaccine strains (K2 and H120) are underlined. The provisional designations, including genogroups and subgenogroups, are indicated on the right.

Statistical Analysis {#cesec80}
--------------------

The reisolation rate of the challenge virus among groups was analyzed using one-tailed Fisher\'s exact test. A *P*-value of \< 0.05 was considered to be statistically significant.

RESULTS {#cesec90}
=======

Phylogenetic Analysis of IBV Isolates {#cesec100}
-------------------------------------

A phylogenetic tree was generated to describe the relationship between nucleotide sequences of the *S1* gene of IBV isolates and other field strains. The Korean IBV strains were divided into 2 distinct genetic groups: Korean group 1 (K-1) and Korean group 2 (K-2). The K-1 included respiratory strains, whereas all nephropathogenic strains were included in K-2. In addition, K-2 was divided into 2 separate subgroups: KM91-like and QX-like. A phylogenetic analysis showed that recent IBV isolates formed 2 different clusters, new genetic cluster 1 and 2, which were distinct from other preexisting clusters of Korean IBV ([Figure 1](#fig1){ref-type="fig"}). The IBV isolates belonging to the new cluster 1 shared 88.7 to 90.7% nucleotide similarity to the *S1* gene of the KM91 and QXIBV strains. The IBV strains belonging to the new cluster 2 showed nucleotide identities of \<66% compared with all reference strains used in this study, but they were closely related to Chinese strains, with 95.7 to 98.6% similarity (CK/CH/GD/KP10, CK/CH/GD/NC10, CK/CH/SD09/005, and TC07--2).

Comparison of Amino Acid Sequences of S1 Gene {#cesec110}
---------------------------------------------

The nucleotide and predicted amino acid sequences of the S1 glycoprotein from 23 IBV field isolates were determined and compared. The IBV isolates of new genetic cluster 1 had 91.7 to 99.8% similarity within the same cluster, and amino acid identities of the *S1* gene among the IBV isolates of new genetic cluster 2 ranged from 92.3 to 99.8%. The IBV isolates belonging to new genetic cluster 1 shared 78.9 to 80.6% amino acid similarity to S1 from the H120 strain and 88.1 to 90.9% similarity to that of the K2 strain. The IBV isolates belonging to new genetic cluster 2 possessed low amino acid identity (\<58.7% similarity) to the 2 vaccine strains (H120 and K2). In particular, the challenge strains K716/05, K40/09, and K245/09 of new cluster 1 shared 79.6, 80.4, and 78.9% amino acid similarity to S1 from the H120 strain and 88.8, 90.9, and 89.6% similarity to that of the K2, respectively. The challenge strain K26/10 of new cluster 2 had 57.9% and 58.1% amino acid similarity to S1 from the H120 and K2 vaccine strains, respectively.

Cross-Protective Efficacy of Commercial IBV Against Challenge with New IBV Isolates {#cesec120}
-----------------------------------------------------------------------------------

We evaluated the efficacy of vaccine strains through reisolation of the challenge strain. Five days after the challenge, we reisolated the challenge virus from the tracheas and kidneys of birds. None of the birds showed clinical signs or mortality. The results shown in [Table 2](#tbl2){ref-type="table"} implied that recombinant strains belonging to new genetic cluster 1 possessed high tropism to the trachea and kidney, whereas variant strains belonging to new genetic cluster 2 displayed high tropism only for the trachea. These findings corresponded to clinical lesions of field cases. Nearly all of the recombinant strains produced respiratory signs and nephropathogenicity in chicken farms, and variant strains showed clinical signs that were limited to the respiratory tract ([Table 1](#tbl1){ref-type="table"}).

In groups of chickens vaccinated with H120, incomplete protection against recombinants and variants was observed at both the trachea and kidney. However, chickens immunized with K2 showed significantly higher levels of protection against the challenge with all of the viruses at the trachea and kidney levels (*P* \< 0.05 or better) compared with that of chickens immunized with H120.

DISCUSSION {#cesec130}
==========

Nephropathogenic strains of different serotypes are a major problem worldwide. In particular, outbreaks of QX-like nephropathogenic strains have been reported in many countries, including China ([@bib25]), Thailand ([@bib27]), Russia ([@bib3]), the United Kingdom ([@bib12]), Italy ([@bib1]), Germany, France, and the Netherlands ([@bib16]), in recent years. These strains are continuously evolving and producing new variants as a feature of avian coronaviruses ([@bib17]). The present study also demonstrates that circulating QXIBV-like strains have increased the diversity of Korean IBV strains through recombination with heterologous strains (KM91-like strains) that are classified into different genetic groups.

The sequence data of this study demonstrate that the S1 amino acid sequences of IBV strains belonging to the new cluster 2 display nucleotide identities of \<65% compared with those of all known IBV strains, except 4 strains that were recently isolated from China ([@bib21]). A previous study indicated that a recent Korean IBV isolate (Kr/D64/05) was closely related to the China CK/CH/LDL/97I-type strains ([@bib18]), and the prevalence of QX-like IBV strains in Korea is reminiscent of the spread of the China QXIBV strain in many Eurasian countries ([@bib1]; [@bib12]). The origin of this variant IBV strain is unclear, but the geographical closeness between China and Korea might have fostered IBV transmission and exchange of IBV genetic material. Furthermore, migrating birds are considered to be potential vectors of IBV due to the ability of IBV to replicate even in an asymptomatic teal, which is a member of the largely migratory order Anseriformes ([@bib23]). Therefore, we cannot exclude the possibility of spread of IBV over long distances by wild birds.

The emergence of new infectious bronchitis serotypes creates difficulties in the design of adequate vaccination programs ([@bib24]). However, development of vaccines against new IBV variants is not generally an option, owing to the high cost and time required for their final approval ([@bib15]; [@bib2]). Some IBV vaccine strains from a certain serotype may provide protection against IBV strains not belonging to that serotype ([@bib8]). Thus, performing protection studies (protectotype) with new IBV isolates is a highly relevant and practical method in control strategies of IBV, because it provides direct information about the efficacy of currently available IBV vaccines. In the present study, IBV isolates belonging to new clusters showed low amino acid homology compared with the 2 vaccine strains (H120 and K2 strain), but the K2 strain could provide greater protection against the challenge with recombinant strains K716/05, K40/09, and K245/09 and variant strain K26/09 than that conferred by the commercial H120 vaccine. As already proposed, good protection can be achieved by vaccines containing serotypes that differ both antigenically and genetically from the challenge virus ([@bib8]). The reason might be that, despite extensive differences in the S1 protein, much of the virus genome remains unchanged and there are epitopes in common among different strains of IBV, which play a major role in protective immunity ([@bib6]).

To date, the Mass strains have been primarily used as live vaccines due to their epizootic distributions and cross-protective ability ([@bib14]; [@bib2]). Despite the widespread use of vaccines, outbreaks related to nephropathogenic strains of different serotypes have increased in many countries ([@bib20]; [@bib25]). In Europe, a combination of the Mass and 4/91 vaccine regimen have prevented nephropathogenic IBV infection ([@bib29]). However, the use of multiple strains of live vaccines raises concerns regarding the formation of variant viruses by recombination with field strains resulting from the spread of vaccine strains ([@bib10]). Furthermore, use of 4/91 strains is prohibited in some countries, including Korea, due to the absence of its outbreak in fields. Previous studies demonstrated that the highly attenuated nephropathogenic IBV vaccine strain K2 provides great protection against 2 distinct subgroups of nephropathogenic strains (KM91-like and QX-like; [@bib19]). Moreover, a present study revealed that the K2 strain has a broad cross-protective ability against nephropathogenic recombinant and variant strains. Therefore, a single administration of the K2 strain might be effective and suitable for application in many countries where the nephropathogenic IBV infection is a major problem.

In conclusion, field IBV undergo genetic recombination and evolution, which might lead to disease control difficulty. Thus, examination of the protection conferred by commercially available IBV vaccines against new variants provides important information on control strategies against IBV infection. Based on the data presented in this study, it can be concluded that the K2 vaccine strain confers broad cross protection against a challenge with new variant strains. This information may be helpful for the reduction of economic losses caused by newly evolving nephropathogenic strains and variant IBV.
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[^1]: RS = respiratory signs; ED = egg drop; N = nephritis.

[^2]: Tra = trachea; Kid = kidney; CT = cecal tonsil.

[^3]: Three-wk-old chickens were immunized with IBV, H120, and K2 (10^3.0^ 50% egg infective dose per bird) via the intraocular route. At 3 wk postimmunization, all birds were challenged with 10^4.5^ EID~50~ of 4 new Korean IBV strains via the intraocular route. Five days after challenge, protection was evaluated by the absence of the challenge virus in the kidney and trachea.

[^4]: *P* \< 0.05,

[^5]: *P* \< 0.01,

[^6]: *P* \< 0.001, by Fisher\'s exact test, compared with nonvaccinated control group.

[^7]: *P* \< 0.05,

[^8]: *P* \< 0.01,

[^9]: *P* \< 0.001, by Fisher\'s exact test, compared with the H120 vaccinated group.
